Amalgamated Bank raised its stake in Blueprint Medicines Corp (NASDAQ:BPMC) by 16.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,777 shares of the biotechnology company’s stock after buying an additional 837 shares during the period. Amalgamated Bank’s holdings in Blueprint Medicines were worth $436,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Blueprint Medicines by 57.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after buying an additional 680 shares during the last quarter. First Mercantile Trust Co. bought a new position in shares of Blueprint Medicines in the 4th quarter worth $183,000. Tower Research Capital LLC TRC increased its holdings in shares of Blueprint Medicines by 942.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock worth $190,000 after buying an additional 2,272 shares during the last quarter. Turner Investments LLC bought a new position in shares of Blueprint Medicines in the 3rd quarter worth $209,000. Finally, Public Employees Retirement Association of Colorado bought a new position in shares of Blueprint Medicines in the 4th quarter worth $227,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently commented on BPMC shares. JMP Securities increased their price target on shares of Blueprint Medicines from $88.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 11th. ValuEngine cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub cut shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Raymond James Financial set a $82.00 price objective on shares of Blueprint Medicines and gave the company a “buy” rating in a research note on Sunday, December 10th. Finally, Zacks Investment Research raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a research note on Monday, January 8th. Two analysts have rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $84.20.
Shares of Blueprint Medicines Corp (BPMC) opened at $99.52 on Friday. Blueprint Medicines Corp has a 12 month low of $34.38 and a 12 month high of $109.00. The stock has a market cap of $4,356.42, a price-to-earnings ratio of -25.58 and a beta of 1.01. The company has a quick ratio of 15.98, a current ratio of 15.98 and a debt-to-equity ratio of 0.02.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.07) by ($0.16). Blueprint Medicines had a negative net margin of 691.30% and a negative return on equity of 38.79%. The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $5.28 million. During the same period last year, the company posted ($0.75) EPS. Blueprint Medicines’s revenue for the quarter was down 78.8% on a year-over-year basis. analysts forecast that Blueprint Medicines Corp will post -4.85 earnings per share for the current fiscal year.
In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $92.57, for a total transaction of $1,851,400.00. Following the completion of the sale, the chief executive officer now owns 20,000 shares of the company’s stock, valued at approximately $1,851,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Lynch sold 17,500 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $74.84, for a total transaction of $1,309,700.00. Following the sale, the director now directly owns 202,812 shares of the company’s stock, valued at approximately $15,178,450.08. The disclosure for this sale can be found here. Insiders have sold a total of 81,775 shares of company stock valued at $6,871,251 in the last three months. 3.40% of the stock is currently owned by corporate insiders.
WARNING: “Blueprint Medicines Corp (BPMC) Shares Bought by Amalgamated Bank” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/03/17/blueprint-medicines-corp-bpmc-shares-bought-by-amalgamated-bank.html.
Blueprint Medicines Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.